Pancreatic Cancer Research

ResearcherJichi Medical UniversityActive in the last 2 years

Naohiro Sata

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6689-5623; OpenAlex author ID A5053746579. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
78
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 3 papers · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 18

  1. Real-world oncological and pathological outcomes after neoadjuvant chemotherapy with gemcitabine plus S-1 for resectable pancreatic cancer: A propensity score-… Co-author DOI 10.1016/j.suronc.2026.102386↗
  2. Diagnostic Biomarkers for Pancreatic Ductal Adenocarcinoma Using Non-Targeted Metabolomic Analysis. Co-author DOI 10.3390/cancers18040684↗
  3. Metformin reshapes the tumor microenvironment and enhances prognosis in invasive pancreatic ductal adenocarcinoma with diabetes mellitus. Last author DOI 10.21037/jgo-2025-457↗
  4. Pancreatic Ductal Adenocarcinoma with Autoimmune Pancreatitis: A Case Report and Literature Review. Co-author DOI 10.2169/internalmedicine.4361-24↗
  5. Combined Intraperitoneal Paclitaxel and Systemic Chemotherapy for Patients with Massive Malignant Ascites Secondary to Pancreatic Cancer: A Report of Two Patie… Last author DOI 10.2169/internalmedicine.2191-23↗
  6. Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical out… Co-author DOI 10.1002/cnr2.1507↗
  7. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group… Co-author DOI 10.1093/jjco/hyaa198↗
  8. Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer: An Integrated Analysis of Data From 2 Clinical Trials. Co-author DOI 10.1097/mpa.0000000000001879↗
  9. Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy. Co-author DOI 10.1111/cas.14258↗
  10. A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-018-3577-9↗
  11. Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (… Co-author DOI 10.1016/j.ejca.2018.01.081↗
  12. Metastasis of pancreatic cancer within primary colon cancer by overtaking the stromal microenvironment. Co-author PMID 31938443↗
  13. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics. Co-author DOI 10.1016/j.cca.2017.02.011↗
  14. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Co-author DOI 10.1016/s0140-6736(16)30583-9↗
  15. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-B… Co-author DOI 10.1371/journal.pone.0161009↗
  16. Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms. Co-author DOI 10.1038/srep15921↗
  17. Altered plasma apolipoprotein modifications in patients with pancreatic cancer: protein characterization and multi-institutional validation. Co-author DOI 10.1371/journal.pone.0046908↗
  18. Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer. Co-author DOI 10.1158/1055-9965.epi-10-0397↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hironori Yamaguchi · 4 shared papers, 2024–2026 · strength 0.90
  2. Shoji Nakamori · 11 shared papers, 2011–2022 · strength 0.68
  3. Joji Kitayama · 3 shared papers, 2024–2026 · strength 0.67
  4. Masanobu Taguchi · 3 shared papers, 2025–2026 · strength 0.66
  5. Akira Fukutomi · 6 shared papers, 2016–2022 · strength 0.50
  6. Takuji Okusaka · 8 shared papers, 2011–2021 · strength 0.44
  7. Yoshiyuki Meguro · 2 shared papers, 2024–2026 · strength 0.42
  8. Tatsuya Ioka · 7 shared papers, 2011–2021 · strength 0.37
  9. Narikazu Boku · 4 shared papers, 2016–2022 · strength 0.30
  10. Katsuhiko Uesaka · 4 shared papers, 2016–2022 · strength 0.30
  11. Yukiyasu Okamura · 4 shared papers, 2016–2022 · strength 0.30
  12. Soichiro Morinaga · 4 shared papers, 2016–2022 · strength 0.30
  13. Kenichi Aizawa · 1 shared paper, 2026 · strength 0.28
  14. Hirofumi Sonoda · 1 shared paper, 2026 · strength 0.28
  15. Nobumasa Mizuno · 3 shared papers, 2018–2021 · strength 0.27
  16. Hiroshi Ishii · 3 shared papers, 2018–2021 · strength 0.27
  17. Masafumi Ikeda · 3 shared papers, 2018–2021 · strength 0.27
  18. Junji Furuse · 3 shared papers, 2018–2021 · strength 0.27
  19. Makoto Ueno · 3 shared papers, 2018–2021 · strength 0.27
  20. Atsushi Kanno · 1 shared paper, 2025 · strength 0.23
  21. Hironori Yamamoto · 1 shared paper, 2025 · strength 0.23
  22. Yusuke Sakurai · 1 shared paper, 2025 · strength 0.23
  23. Noriyoshi Fukushima · 1 shared paper, 2025 · strength 0.23
  24. Naoki Sano · 1 shared paper, 2025 · strength 0.23
  25. Rei Takahashi · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.